tbuckley/cabot-search huggingface dataset:
CIVIL RIGHTS
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Trichinosis from bear meat: clinical and laboratory features
Authors: M. Wand
Journal: JAMA (1972)

Twenty-three people were involved in an outbreak of trichinosis due to ingestion of bear meat. Of 18 persons who ate uncooked meat, 12 developed fever, myalgia, periorbital edema, and eosinophilia. All had positive skin-tests, and ten had positive bentonite-flocculation-tests (BFTs). Of the 11 asymptomatic patients, including all five who had eaten only cooked meat, six had tests negative to both, and five had positive skin tests or BFTs or both.
Poster Session 1: Living Donors and Split Transplant
Authors: Jin Li, Yingli He, Dan Du, Yuanyuan Li, Ruitian Yi, Jing Wang, Tianyan Chen, Yingren Zhao, Astrid Kosters, Demesew Abebe, Julio Felix, Saul Karpen, Murat Dayangac, Murat Akyildiz, Yalcin Erdogan, Gokhan Gungor, Yaman Tokat, Fatima Rehman, Toshiyuki Hata, Zhaoyu Li, Guojun Bu, Justin Nguyen
Journal: Hepatology (2014)

509Awhile IL-6 and MELD scores were still higher than CHB patients (p=0.000).In addition, on the peak ACLF severity, the concentrations of IFN-γ, IL-6 and IL-10 were positive correlation with MELD scores (R=0.514,P=0.05; R=0.518, P=0.048; R=0.629, P=0.012, respectively), while the rates of IFN-γto IL-10 and IFN-γto IL-6 were negative correlation to MELD scores (R=-0.564,P=0.028; R=-0.531,P=0.042, respectively).Conclusions: Th1/Th2/Th17 the cytokines were raised in the acute phase of ACLF and exhausted quickly, which were paralleled with MELD scores.Th2 cytokines such as IL6 and IL10 were associated with aggravation of ACLF.
SOCIETY PROCEEDINGS: ASSOCIATION OF AMERICAN MEDICAL COLLEGES.
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmacologic Aspects of Adrenocortical Steroids and ACTH in Man
Authors: George W. Thorn, Dalton Jenkins, John C. Laidlaw, Frederick C. Goetz, Joseph F. Dingman, Walter L. Arons, David H. P. Streeten, Brian H. McCracken
Journal: New England Journal of Medicine (1953)

CLINICAL USES OF ACTH, CORTISONE AND HYDROCORTISONESpecific Replacement Therapy Primary Adrenal Insufficiency The use of cortisone has greatly improved the effectiveness of replacement therapy in patients with Addison's disease.47 Although treatment with desoxycorticosterone unquestionably prolonged the life of many of these patients, cortisone has corrected important metabolic defects not affected by desoxycorticosterone: the facilitation of gluconeogenesis, the restoration of water metabolism to normal and the correction of the electroencephalographic abnormalities of Addison's disease. Appetite, muscular strength and work tolerance are improved, and anemia is diminished. These changes, in conjunction with the remarkable sense of well-being imparted by cortisone, have . . .
P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial
Authors: C. L. Schwartz, L. H. Wexler, M. Devidas, A. Goorin, H. Grier, P. Meyers, M. Bernstein
Journal: Journal of Clinical Oncology (2004)

8514 Background: Outcome in osteosarcoma (OS) is predicted by percent necrosis (% NEC) after pre-operative chemotherapy. Efforts to improve outcome by post-operative therapeutic intensification have had limited success. Historically, 70% are standard responders (SR: < 98% NEC) whose outcomes justify efforts to intensify therapy. Methods: Patients <31 yrs diagnosed with non-metastatic OS were eligible for P9754. The objectives were 1) to assess feasibility of dose intensified regimens for SR and 2) to determine whether the cardioprotectant dexrazoxane (DXR) would adversely impact % NEC vs. historical outcomes. All received doxorubicin (75 mg/m2/cycle × 6; each dose with DXR), methotrexate (12 mg/m2 [20 mg max] × 10), cisplatin (120 mg/m2/cycle × 4). Pilots 2 and 3 also included "standard" ifosfamide (9 g/m2/cycle × 3–4). Three sequential pilots evaluated intensified therapy for SR: 1) Doxorubicin intensification to a cumulative dose of 600mg/m2 on Pilots 1 and 2; or 2) 3 cycles of etoposide (500mg/m2 /cycle) and high dose ifosfamide (14 g/m2/cycle) on Pilot 3. Results: Original accrual projections were 60 patients/pilot. Accrual to pilot 1 was doubled to assess toxicity of increased doxorubicin (to 600 mg/m2). 242 of 253 enrolled patients were eligible; 221 were assessable for major study endpoints (111, 54, 56 on pilots 1, 2, 3 ). Good Response (GR: > 98% NEC) to preoperative chemotherapy was noted in 30.2%, with 61.2% SR and 8.7% not evaluable (surgery not performed at time stipulated by protocol). Left ventricular dysfunction, ototoxicity and renal toxicity (Fanconi syndrome, decreased GFR) were not significantly increased by intensification. One secondary leukemia was reported (Pilot 2). Dose intensification by increased cumulative doxorubicin or by etoposide with high-dose ifosfamide was feasible. Two year EFS was 69%. Conclusions: Dexrazoxane permitted the safe escalation of cumulative doxorubicin dose without adverse effect on % NEC after pre-operative chemotherapy. Dose intensification with either higher cumulative doxorubicin dose or etoposide/high dose ifosfamide was clinically feasible. 2-yr EFS was NSS different between pilots. No significant financial relationships to disclose.
New Rule on Labeling Foods as 'Healthy' Issued
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutagenic Activities of Heterocyclic Amines in Chinese Hamster Lung Cells in Culture
Authors: Masaaki Terada, Minako Nagao, Michie Nakayasu, Hiromi Sakamoto, Fumiko Nakasato, Takashi Sugimura
Journal: Environmental Health Perspectives (1986)

A mutation assay system with Chinese hamster lung cells (CHL) using diphtheria toxin resistance as a selective marker has been established. The mutagenic activities of heterocyclic amines, originally isolated from pyrolyzates of amino acids and proteins, broiled fish and fried beef were assayed in cultured CHL cells in the absence and presence of a metabolic activation system, with diphtheria toxin resistance as a marker. All the heterocyclic amines tested except 3-amino-1,4-dimethyl-5H-pyrido [4,3-b]indole (Trp-P-1) required the presence of a metabolic activation system for mutagenicity on CHL cells. 3-Amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2) was the most mutagenic among the heterocyclic amines tested. Other compounds were also mutagenic in the following order of decreasing potency: Trp-P-1, 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), 2-amino-9H-pyrido[2,3-b]indole (A alpha C), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1) and 2-aminodipyrido[1,2-a:3',2'-d]imidazole (Glu-P-2).
Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel
Authors: S Nagafuchi, S Kashiwagi, K Okada, K Anzai, M Nakamura, Y Nishimura, T Sasazuki, Y Niho
Journal: JAMA (1991)

Thirty-one Japanese nonresponders to subcutaneous hepatitis B vaccination and 15 medical personnel who were accidentally exposed to specimens positive for hepatitis B e antigen and were given hepatitis B immunoglobulin were intradermally immunized with 5 micrograms of plasma-derived hepatitis B vaccine every 2 weeks until delayed type hypersensitivity skin reaction to hepatitis B surface antigen became positive. Thirty (97%) of the 31 nonresponders developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen after 2.3 +/- 1.2 (mean +/- SD) revaccinations. Twenty-nine (94%) of the 31 nonresponders had anti-hepatitis B surface antigen antibody levels greater than 10 IU/L. The immunoglobulin subclass of the antibody to hepatitis B surface antigen was mainly IgG1. After 1 year, 23 (74%) of the 31 nonresponders continued to have anti-hepatitis B surface antigen antibody levels greater than 10 IU/L. Persons accidentally exposed to specimens positive for hepatitis B e antigen developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen following 3.1 +/- 1.1 revaccinations. None developed clinical hepatitis. There was no production of anti-hepatitis B core antigen antibody 1 year after exposure, indicating that protection was 100%. Intradermal hepatitis B vaccination is useful in reversing nonresponsiveness to hepatitis B surface antigen and for prophylaxis after exposure.
COMING MEETINGS
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book: Biohazard
Authors: F. Charatan
Journal: BMJ (1999)

Ken Alibek, Stephen Handelman Hutchinson, £17.99, pp 330 ISBN 0 09 180085 4 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img>![Graphic][4]</img> Ken Alibek, formerly Kanatjan Alibekov, was born in Kauchuk, Kazakhstan, in 1950. He graduated from the Tomsk Medical Institute in 1975. He holds PhDs in microbiology and biotechnology. He joined the Soviet Union's Biopreparat in 1975 and was deputy chief of the agency from 1988 to 1992, when he defected to the United States. Biopreparat is “the Soviet state pharmaceutical agency whose primary function was to develop and produce weapons made from the most dangerous viruses, toxins, and bacteria known to man.” It is spread over 40 sites, many in European Russia, including Moscow and Leningrad. Alibek writes: “Over a twenty year period that began, ironically, with Moscow's endorsement of the Biological Weapons Convention in 1972, the Soviet Union built the largest and most advanced biological warfare establishment … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif [4]: /embed/inline-graphic-4.gif
Motivation in drug misuse. Some comments on agent, environment, host
Authors: E. Lipinski
Journal: JAMA (1972)

The public health paradigm of three interacting systems, agent, host, and environment, is utilized as an explanatory framework to focus on complex psychosocial factors in psychotropic drug misuse. Emphasis is given to (1) rapid changes in the drug scene, (2) varying motivation for use of different drugs, and (3) changes in motivation after initial drug use. A decade ago drug use was primarily determined by personal needs and motives. Today, with increasing use of drugs for nonmedical purposes, redefinition of illness, and a widespread expectation that human problems will be changed or solved through chemistry, the general psychosocial and economic mileu predisposes the public to widespread nonmedical drug use.
More To Learn from Mary's Story
Authors: Emily A. Blumberg
Journal: Annals of Internal Medicine (1993)

Letters1 September 1993More To Learn from Mary's StoryEmily A. Blumberg, MDEmily A. Blumberg, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-5-199309010-00038 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Dr. Southwick's article [1] poignantly described a not uncommon, major conflict in the practice of academic medicine. I noted a similar pattern of attending non-involvement when my father was critically ill at a major oncology center. The center had a policy that made it almost impossible for a family member to speak with the attending who was nominally in charge of the patient's case, even when that family member was an attending at another academic center. On one occasion, I had to completely misrepresent my identity just to speak with the fellow covering the service during a ...REFERENCE1. Southwick F. Who was caring for Mary? Ann Intern Med. 1993; 118: 146-8. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1993Volume 119, Issue 5Page: 441-442KeywordsAcademic medicinePatients ePublished: 15 August 2000 Issue Published: 1 September 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Clinical laboratory use in the evaluation of anemia
Authors: L. A. Wheeler
Journal: JAMA (1977)

Follow-up tests ordered on 258 consecutively examined inpatients with low hemoglobin values on admission were analyzed. The appropriateness of the follow-up tests was evaluated by chart review after preselection by an algorithm. When the cause of the anemia was known or was irrelevant in view of the patient's clinical status, the laboratory use was judged to be adequate. Seventy-one percent of patients studied had an adequate follow-up, though 11% had nonindicated tests performed, scored as laboratory overuse. Twenty-four percent had no follow-up, scored as laboratory underuse. Five percent did not have all indicated tests done and had nonindicated tests done, scored as a mixture of underuse and overuse. Potential remedies to correct misuse are discussed. (<i>JAMA</i>238:2709-2714, 1977)
Phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients progressing after docetaxel treatment: Preliminary toxicity analysis (SOGUG-CABASEM trial).
Authors: Miguel Angel Climent Duran, Begoña Perez-Valderrama, Eva Fernandez Parra, Begoña Mellado, Montserrat Domenech, Ovidio Fernandez Calvo, Urbano Anido, Susana Hernando Polo, Jose Angel Arranz, Cristina Caballero, Maria Ochoa de Olza, Daniel E. Castellano
Journal: Journal of Clinical Oncology (2014)

190 Background: Docetaxel (D) is standard first-line chemotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Cabazitaxel (C), a novel taxane developed to overcome D resistance, showed an overall survival improvement in second line CRPC in a three-weekly dose schedule. Its main toxicity is hematological, especially in unfit patients. We aimed to evaluate efficacy and safety of weekly C/pred. in "unfit" mCRPC previously treated with D. Methods: Unfit pts (ECOG 2, dose reduction due to febrile neutropenia during treatment with D or radiation therapy affecting more than 25% of bone marrow reserve) with advanced CRPC progressing after D treatment with ECOG &lt;=2 and adequate bone marrow, liver and kidney functions were included. C 10 mg/m2 was administered on days 1, 8, 15, and 22 of 5-week cycles with daily pred. 5 mg b.i.d. Radiological and prostate-specific antigen response was evaluated according to the PCCTWG II criteria and toxicity according NCI-CTC AE. Results: To date 47 pts have been enrolled and data are available for 38. Median age was 72 (range 56 to 83), 20 (53%) pts had ECOG 2, 29 (83%) had bone metastases. Cycles administered: 124 (median: 3; range: 1 to 9) and 446 weekly administrations (median 11; range 1 to 35). Mean dose intensity was 94%. Most frequent toxicities of all grades as % of cycles were: asthenia (20%), anemia (50%), leukopenia (13%), thrombocytopenia (14%), diarrhea (9%), rash (6%), nauseas (5%), dysgeusia (7%), xerostomia (6%), anorexia (5%), hand-foot syndrome (5%), and neuropathy (2%). Grade 3: thrombocytopenia (10%), anemia (6%), neutropenia (1%), asthenia (3%), anorexia (1%), mucositis (1%), nausea (1%), and vomiting (1%). No grade 4 toxicities were reported. Three patients discontinued the study due to asthenia G3 (2) and mucositis G3 (1). No grade III/IV diarrhea or febrile neutropenia were observed. Conclusions: Administration of weekly C (10 mg/m2) to unfit pts seems to be safe with no grade 3 or greater neutropenia, diarrhea, or febrile neutropenia reported. If activity is confirmed, weekly C may represent an attractive option for unfit pts with mCRPC progressing after D treatment. Clinical trial information: NCT01518283.
EXPERIMENTAL STUDY OF TOXIC ANEMIA.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ALLERGY IN DISEASES OF THE SKIN
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OFFICIAL CALL
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal